Condition
Advanced Solid Tumor Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 6 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
6 shownThe EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced CancerNCT07636200 · 2026-05-04
RECRUITINGTrastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard TherapiesNCT07309770 · 2025-12-18
RECRUITINGA Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung CancerNCT07381829 · 2025-10-27
RECRUITINGX-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and MelanomaNCT04389281 · 2021-12-08
RECRUITINGStudy With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsNCT04777994 · 2021-03-09
RECRUITINGTislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System DiseaseNCT07681297 · 2026-08-01
NOT_YET_RECRUITINGCommon interventions
ABBV-CLS-484DRUG1Carboplatin/CisplatinDRUG1DocetaxelDRUG1EtoposideDRUG1HC010DRUG1Paclitaxel (Chemotherapy)DRUG1PemetrexedDRUG1Programmed Cell Death-1 (PD-1) InhibitorDRUG1SHR-A1811DRUG1Tislelizumab + Bevacizumab + CapecitabineDRUG1Trastuzumab RezetecanDRUG1Usual Care Control ConditionBEHAVIORAL1Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)DRUG1Written Exposure-Based Coping Intervention (EASE)BEHAVIORAL1X-PACTCOMBINATION_PRODUCT1
Leading sponsors
Trial status mix
RECRUITING5
NOT_YET_RECRUITING1
Phase mix
PHASE14
PHASE22
NA1
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.